Emerging therapeutic strategies for Fragile X Syndrome: Q&A

Ghassan Alusi, Elizabeth Berry-Kravis, David Nelson, Lauren L Orefice, Sam A Booker*

*Corresponding author for this work

Research output: Contribution to journalComment/debate

Abstract / Description of output

Understanding how best to treat aspects of Fragile X syndrome has the potential to improve the quality of life of affected individuals. Such an effective therapy has, as yet, remained elusive. In this article, we ask those researching or affected by Fragile X syndrome their views on the current state of research and from where they feel the most likely therapy may emerge.
Original languageEnglish
Pages (from-to)3544-3546
JournalACS Chemical Neuroscience
Issue number24
Early online date7 Dec 2022
Publication statusPublished - 21 Dec 2022

Keywords / Materials (for Non-textual outputs)

  • Fragile X syndrome
  • arbaclofen
  • fragile X messenger ribonucleoprotein 1
  • neurodevelopmental conditions
  • phosphodiesterase
  • somatosensation


Dive into the research topics of 'Emerging therapeutic strategies for Fragile X Syndrome: Q&A'. Together they form a unique fingerprint.

Cite this